CN113662044A - Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof - Google Patents
Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof Download PDFInfo
- Publication number
- CN113662044A CN113662044A CN202110931305.4A CN202110931305A CN113662044A CN 113662044 A CN113662044 A CN 113662044A CN 202110931305 A CN202110931305 A CN 202110931305A CN 113662044 A CN113662044 A CN 113662044A
- Authority
- CN
- China
- Prior art keywords
- powder
- children
- parts
- milk powder
- formula milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 261
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 62
- 238000011161 development Methods 0.000 title claims abstract description 36
- 230000001737 promoting effect Effects 0.000 title claims abstract description 28
- 230000036039 immunity Effects 0.000 title claims abstract description 26
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 48
- 235000013336 milk Nutrition 0.000 claims abstract description 45
- 239000008267 milk Substances 0.000 claims abstract description 45
- 210000004080 milk Anatomy 0.000 claims abstract description 45
- 229960003080 taurine Drugs 0.000 claims abstract description 24
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 21
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 21
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 21
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 21
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 20
- 239000011575 calcium Substances 0.000 claims abstract description 20
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000006071 cream Substances 0.000 claims abstract description 19
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims abstract description 18
- 235000012680 lutein Nutrition 0.000 claims abstract description 18
- 229960005375 lutein Drugs 0.000 claims abstract description 18
- 239000001656 lutein Substances 0.000 claims abstract description 18
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 18
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 18
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 18
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 18
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 17
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 14
- 239000000839 emulsion Substances 0.000 claims abstract description 3
- 235000020185 raw untreated milk Nutrition 0.000 claims description 20
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 16
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 16
- 239000011812 mixed powder Substances 0.000 claims description 14
- 210000003022 colostrum Anatomy 0.000 claims description 12
- 235000021277 colostrum Nutrition 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 244000144730 Amygdalus persica Species 0.000 claims description 9
- 244000099147 Ananas comosus Species 0.000 claims description 9
- 235000007119 Ananas comosus Nutrition 0.000 claims description 9
- 241000167854 Bourreria succulenta Species 0.000 claims description 9
- 235000004936 Bromus mango Nutrition 0.000 claims description 9
- 235000009467 Carica papaya Nutrition 0.000 claims description 9
- 235000005979 Citrus limon Nutrition 0.000 claims description 9
- 244000131522 Citrus pyriformis Species 0.000 claims description 9
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 9
- 240000002319 Citrus sinensis Species 0.000 claims description 9
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 9
- 240000009088 Fragaria x ananassa Species 0.000 claims description 9
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 9
- 240000007228 Mangifera indica Species 0.000 claims description 9
- 235000014826 Mangifera indica Nutrition 0.000 claims description 9
- 240000008790 Musa x paradisiaca Species 0.000 claims description 9
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 9
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 9
- 241000287420 Pyrus x nivalis Species 0.000 claims description 9
- 235000009184 Spondias indica Nutrition 0.000 claims description 9
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 9
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 9
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 9
- 241001593968 Vitis palmata Species 0.000 claims description 9
- 235000021014 blueberries Nutrition 0.000 claims description 9
- 235000019693 cherries Nutrition 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 240000006432 Carica papaya Species 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 15
- 235000015097 nutrients Nutrition 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 7
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 239000013589 supplement Substances 0.000 abstract description 6
- 230000035764 nutrition Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000005784 autoimmunity Effects 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 230000018109 developmental process Effects 0.000 description 32
- 230000000694 effects Effects 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 241000219173 Carica Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002270 gangliosides Chemical class 0.000 description 4
- -1 iron ions Chemical class 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000025402 cranial nerve development Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a children formula milk powder for promoting height development and enhancing immunity and a preparation method thereof, wherein the children formula milk powder comprises the following components in parts by weight: 80-120 parts of milk powder, 2-6 parts of anhydrous cream, 0.005-0.015 part of lactoferrin, 0.03-0.06 part of hydrolyzed yolk powder, 0.01-0.05 part of DHA, 1-2 parts of milk calcium, 0.05-0.15 part of fruit powder, 0.015-0.03 part of primary emulsion basic protein, 0.003-0.010 part of N-acetylneuraminic acid, 0.005-0.015 part of lutein and 0.005-0.015 part of taurine; the children formula milk powder can supplement nutrition required by growth and development of children through selection of all raw materials, and is rich in nutrient substances and easy to absorb; in addition, the children formula milk powder also contains nutrient substances required by immune system establishment, and the combined action of all the components can effectively improve the autoimmunity of children and enhance the physique; the children formula milk powder can effectively promote the thriving of children and the growth of the height of children under the combined action of nutrient substances, absorption promotion and physique enhancement.
Description
Technical Field
The invention relates to the technical field of milk powder, in particular to children formula milk powder for promoting height development and enhancing immunity and a preparation method thereof.
Background
There are many types of milk powder, such as infant milk powder, senior milk powder, pregnant woman milk powder, adult milk powder, milk calcium powder, etc., which are divided according to the needs of each group to have different effects.
At present, the healthy growth of children is always a common wish of parents, and the parents expect that the children have higher height. There are many auxiliary methods for promoting growth, and the most common choice of parents is that children drink high milk powder to supplement nutrition required by the development of children and promote the growth of children. However, most of the traditional children's high milk powder has the problems of low calcium content, difficult absorption, less nutrient components and poor administration effect, and can not meet the development requirements of children on height.
Disclosure of Invention
The invention aims to provide the children formula milk powder for promoting the growth and development of the body height and enhancing the immunity and the preparation method thereof, the children formula milk powder can supplement the nutrition required by the growth and development of children, and the nutrient substances are rich and easy to absorb; in addition, the children formula milk powder also contains nutrient substances required by immune system establishment, improves the autoimmunity of children, and strengthens physique; the children formula milk powder disclosed by the invention can effectively promote the thriving of children and the growth of the height under the combined action of nutrient substances, high calcium content and physique enhancement.
In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
the invention provides a children formula milk powder for promoting height development and enhancing immunity (the formula of the children formula milk powder can be named as 5S-GAVII, namely 5S-GAVII platinum drilling nutritional formula), which comprises the following components in parts by weight:
80-120 parts of milk powder, 2-6 parts of anhydrous cream, 0.005-0.015 part of lactoferrin, 0.03-0.06 part of hydrolyzed yolk powder, 0.01-0.05 part of DHA, 1-2 parts of milk calcium, 0.05-0.15 part of fruit powder, 0.015-0.03 part of primary emulsion basic protein, 0.003-0.010 part of N-acetylneuraminic acid, 0.005-0.015 part of lutein and 0.005-0.015 part of taurine.
The raw materials adopted in the invention are as follows:
the milk powder is prepared from raw milk, is rich in immunoglobulin, can efficiently resist viruses, bacteria, fungi and other allergens, forms antibodies, neutralizes toxins, strengthens physique, improves immunity and reduces the probability of diseases; in addition, the raw milk is rich in lactoferrin, growth factors and proteins, and the lactoferrin can effectively resist oxidation, eliminate or inhibit bacteria, promote the growth of brain cells, improve memory and improve intelligence quotient; the growth factor and the protein can promote the growth and development of the nervous system, the digestive system, the fiber cell, the skin system and the like in the body, help to repair tissue cells, promote wound healing and accelerate postoperative rehabilitation; the raw milk can also supplement calcium necessary for growth and development and promote the growth and development of bones and teeth.
Lactoferrin has important significance for improving the immunity of non-breast-fed infants. The lactoferrin can effectively help infants to resist bacteria and virus, and help prevent infant diseases caused by viruses; in addition, lactoferrin can generate a synergistic effect with medicines, especially can be well combined with antibiotics and antiviral medicines, the antiviral effect can be well played while the dosage of the medicines is reduced, and the damage of the medicines to the liver and the kidney of a human body can be effectively reduced; the absorption capacity of the body for utilizing the iron element can be improved, particularly, lactoferrin can help to stabilize favorable iron ions when being combined with the iron element, on one hand, the stimulation of the iron ions to the gastrointestinal tract can be reduced, and on the other hand, the absorption of the gastrointestinal tract to the iron ions can be promoted; in addition, lactoferrin can effectively help bacteriostasis mainly because lactoferrin can highly bind to iron elements in the body and block the supply of iron elements necessary for the survival of bacteria; in addition, lactoferrin is able to interfere with proton transfer on the cell membrane to give complete killing of the microorganisms.
The hydrolyzed yolk powder is a functional polypeptide substance extracted from egg yolk, the egg yolk contains components for promoting bone growth, and the hydrolyzed yolk powder is produced by using egg yolk as a raw material and performing protease treatment, heating, centrifugal separation, spray drying and other steps, and is easy to fuse with milk; can increase the number of osteoblasts and promote the generation of bones and teeth; activating the motive power of the skeleton and promoting the elongation of the skeleton; promote the calcium deposition of the skeleton and strengthen the toughness of the skeleton; inhibit the growth of osteoclast and maintain the balance of bone mass.
Colostrum basic protein: promoting osteoblast proliferation, greatly enhancing the absorption and utilization of calcium, and keeping bone density; colostrum Basic Protein (CBP) colostrum is not only high in protein content, but also contains rare proteins that many other dairy products do not; CBP can directly act on bone cells to promote bone metabolism; can coordinate the activities of osteoblast and osteoclast, maintain the dynamic balance of osteoblast and osteoclast, promote the growth of bone, and repair bone.
N-acetylneuraminic acid is a negatively charged ion that produces a smooth sensation in saliva. It not only has the function of inducing invasion of pathogenic bacteria, but also is the transmission transmitter of ganglioside, and is a component of brain. N-acetylneuraminic acid can prevent pathogen invasion. N-acetylneuraminic acid is also a receptor of influenza virus, and is a binding site for the influenza virus to bind in the mucous cells. Gangliosides have a significant effect on the promotion of nerve regeneration. Further research finds that Nerve Growth Factor (NGF) and Ganglioside (GM) are necessary substances for brain nerve regeneration and development, GM mediates the NGF to enhance the activity of the NGF by tens of times, forms a new rich neural network, repairs and promotes brain nerves to develop again, can mediate the nerve growth factor NGF to promote brain nerve cell regeneration, and shows good biological effect.
N-acetylneuraminic acid is viewed from a biological mechanism, and melanin is formed by a black color body in a melanocyte through tyrosinase catalysis, so that the skin color is blackened. Tyrosinase has dual activities of tyrosine hydroxylase, which can convert tyrosine into dopa, and dopa hydroxylase, which converts dopa into dopaquinone. Therefore, the whitening efficacy can be judged according to the influence of the substance on the tyrosinase activity.
In addition, the N-acetylneuraminic acid can be combined with bacteria and viruses, and has the effects of inhibiting and resisting the bacteria and the viruses. Sialic acid is used as an important receptor for a plurality of pathogenic microorganisms to infect organisms, and provides an important research idea for preventing human infectious diseases.
The N-acetylneuraminic acid can also regulate the anti-inflammatory activity of IgG, so that the effect of improving the immunity is achieved; the first line of defense (the blocking effect of skin and mucosa) affecting the immunity of the baby can improve the resistance of the mucosa layer of the respiratory tract.
Lutein plays an important role in protecting macula lutea in retina, and human body can not synthesize by itself, and must be supplemented by taking lutein. If the eyes lack lutein, the symptoms such as visual deterioration, myopia, retinopathy and the like are easily caused; ultraviolet rays and blue light in sunlight enter eyes to generate a large amount of free radicals, so that cataract and macular area are degraded. The lutein in the yellow spots can filter out blue light, so that the damage of the blue light to eyes is avoided, and the effects of delaying the aging of the eyes and preventing the pathological changes of the eyes are achieved. In addition, the lutein has antioxidant and photoprotective effects, can rapidly relieve asthenopia, and improve symptoms such as maculopathy, blurred vision, dry eye, eye swelling, ophthalmalgia, photophobia, etc., to achieve the effect of protecting eyesight. The anthocyanin contained in the lutein is a natural powerful antioxidant, and can effectively reduce the damage of free radicals, enter the circulation of fine blood vessels, improve the flow of the micro blood vessels and veins and protect the micro blood vessels.
Taurine is commonly referred to as an amino acid, and is neither part of the human protein structure nor an essential amino acid. It chemically reacts with glycine and gamma aminobutyric acid and acts as a neuro-inhibitor transporter of tissues and blood. It is an amino acid compound. The heart, skeletal muscles and nervous system contain a large number of these elements. Taurine is also found in bile and serves to promote intestinal digestion and as an emulsifier for dietary fat.
Taurine is also a metabolic transmitter and therefore has detoxifying effects. It has effects in enhancing myocardial contractility and improving exercise ability. Many infant nutritional supplements contain taurine, which results in taurine deficiency because premature infants tend to lack the enzymes that convert cystathionine to cysteine. This amino acid is found in most mammalian milk. It also plays an important role in the human brain, and research shows that taurine is very helpful for manic depression patients. Taurine, because of its anxiolytic properties, is useful as a human nervous system modulator. It has also been found that taurine can be found during brain development, but its concentration decreases after maturation. Taurine is also used to treat heart disease and is of great help to patients with congestive heart failure. In addition to this, it is often used as a therapeutic agent for hypertension and high cholesterol. Research proves that taurine also has the efficacy of reducing blood sugar level, thereby being an effective diabetes treatment drug.
In addition, taurine can maintain the normal functions of human brains, improve memory and promote the intelligence development of infants; the normal maintenance of the visual function is facilitated, the eyesight is protected, the vision is improved, and the normal function of the cell membrane of the human eyes is maintained; also has effects in regulating nerve conduction of human body, and promoting cranial nerve development; and promoting absorption of fat, inhibiting generation of cholelithiasis, enhancing myocardial contraction, lowering blood pressure, lowering blood sugar, protecting heart, and removing toxic substances. Taurine also can promote growth and development, promote the secretion of growth hormone of human body, promote the absorption of iron by intestinal tract, optimize the structure of bacterial flora in intestinal tract and prevent constipation.
Preferably, the children formula milk powder comprises the following components in parts by weight:
90-110 parts of milk powder, 3-5 parts of anhydrous cream, 0.008-0.010 part of lactoferrin, 0.04-0.06 part of hydrolyzed yolk powder, 0.02-0.04 part of DHA, 1.2-1.6 parts of milk calcium, 0.08-0.12 part of fruit powder, 0.02-0.025 part of colostrum basic protein, 0.005-0.010 part of N-acetylneuraminic acid, 0.008-0.012 part of lutein and 0.008-0.012 part of taurine.
Preferably, the children formula milk powder comprises the following components in parts by weight:
100 parts of milk powder, 4 parts of anhydrous cream, 0.010 part of lactoferrin, 0.05 part of hydrolyzed yolk powder, 0.03 part of DHA, 1.5 parts of milk calcium, 0.1 part of fruit powder, 0.022 part of colostrum basic protein, 0.008 part of N-acetylneuraminic acid, 0.01 part of lutein and 0.01 part of taurine.
Preferably, the children formula milk powder further comprises bifidobacterium animalis BB-12, wherein the content of the bifidobacterium animalis BB-12 is (1-10) x 106CFU/g。
The Bifidobacterium animalis Bb-12 has effects of improving intestinal tract and preventing diarrhea, and the Bifidobacterium animalis Bb-12 can help infants maintain gastrointestinal flora health and improve intestinal tract, thereby preventing diarrhea and reducing side effects of antibiotic therapy.
Preferably, the fruit powder comprises at least one of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder.
Preferably, the fruit powder comprises apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder in equal amount.
The invention provides a preparation method of the children formula milk powder, which comprises the following steps:
adding anhydrous cream and DHA into raw milk, homogenizing, sterilizing, concentrating, and spray drying to obtain mixed powder;
and adding the rest components into the mixed powder, uniformly mixing, cooling, and packaging to obtain the children formula milk powder.
Preferably, the homogenizing temperature is 40-60 ℃, and the pressure is 8-20 MPa.
Preferably, the sterilization temperature is 90-93 ℃.
Preferably, the environment temperature of the bean jelly is 15-26 ℃, and the humidity is 45-60%.
Compared with the prior art, the invention has the beneficial effects that at least:
the children formula milk powder can supplement nutrition required by growth and development of children through selection of all raw materials, and is rich in nutrient substances and easy to absorb; in addition, the children formula milk powder also contains nutrient substances required by immune system establishment, and the combined action of all the components can effectively improve the autoimmunity of children and enhance the physique.
The children formula milk powder can effectively promote the thriving of children and the height development of children under the combined action of various aspects of nutrient substances, high calcium content, absorption promotion and physique enhancement.
Detailed Description
The following describes embodiments of the present invention in detail with reference to the following embodiments. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
Children formula milk powder capable of promoting height development and enhancing immunity
The children formula milk powder for promoting height development and enhancing immunity comprises the following components in parts by weight:
120 parts of milk powder, 2 parts of anhydrous cream, 0.015 part of lactoferrin, 0.03 part of hydrolyzed yolk powder, 0.05 part of DHA, 1 part of milk calcium, 0.15 part of fruit powder, 0.015 part of colostrum basic protein, 0.010 part of N-acetylneuraminic acid, 0.005 part of lutein and 0.015 part of taurine; wherein each part of fruit powder comprises equal amount of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder;
the children formula milk powder also comprises Bifidobacterium animalis BB-12, wherein the content of Bifidobacterium animalis BB-12 is 1 × 106CFU/g。
Second, preparation method
The preparation method of the children formula milk powder for promoting height development and enhancing immunity comprises the following steps:
determining the using amount of raw milk corresponding to the milk powder according to the proportional relation of the milk powder prepared from the raw milk, then adding anhydrous cream and DHA into the raw milk, and homogenizing, performing bus disinfection and sterilization, concentrating and spray drying at 50 ℃ and 10MPa to obtain mixed powder;
adding the rest components into the mixed powder, mixing, cooling at 20 deg.C and 50% humidity, and packaging to obtain the children formula milk powder.
Example 2
Children formula milk powder capable of promoting height development and enhancing immunity
The children formula milk powder for promoting height development and enhancing immunity comprises the following components in parts by weight:
80 parts of milk powder, 6 parts of anhydrous cream, 0.005 part of lactoferrin, 0.06 part of hydrolyzed yolk powder, 0.01 part of DHA, 2 parts of milk calcium, 0.05 part of fruit powder, 0.03 part of colostrum basic protein, 0.003 part of N-acetylneuraminic acid, 0.015 part of lutein and 0.005 part of taurine; wherein each part of fruit powder comprises equal amount of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder;
the children formula milk powder also comprises Bifidobacterium animalis BB-12, wherein the content of Bifidobacterium animalis BB-12 is 1 × 107CFU/g。
Second, preparation method
The preparation method of the children formula milk powder for promoting height development and enhancing immunity comprises the following steps:
determining the using amount of raw milk corresponding to the milk powder according to the proportional relation of the milk powder prepared from the raw milk, then adding anhydrous cream and DHA into the raw milk, and homogenizing, performing bus disinfection and sterilization, concentrating and spray drying at 50 ℃ and 10MPa to obtain mixed powder;
adding the rest components into the mixed powder, mixing, cooling at 20 deg.C and 50% humidity, and packaging to obtain the children formula milk powder.
Example 3
Children formula milk powder capable of promoting height development and enhancing immunity
The children formula milk powder for promoting height development and enhancing immunity comprises the following components in parts by weight:
110 parts of milk powder, 3 parts of anhydrous cream, 0.010 part of lactoferrin, 0.06 part of hydrolyzed yolk powder, 0.02 part of DHA, 1.2 parts of milk calcium, 0.12 part of fruit powder, 0.02 part of colostrum basic protein, 0.010 part of N-acetylneuraminic acid, 0.008 part of lutein and 0.012 part of taurine; wherein each part of fruit powder comprises equal amount of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder;
the children formula milk powder also comprises Bifidobacterium animalis BB-12, wherein the content of Bifidobacterium animalis BB-12 is 4 x 106CFU/g。
Second, preparation method
The preparation method of the children formula milk powder for promoting height development and enhancing immunity comprises the following steps:
determining the using amount of raw milk corresponding to the milk powder according to the proportional relation of the milk powder prepared from the raw milk, then adding anhydrous cream and DHA into the raw milk, and homogenizing, performing bus disinfection and sterilization, concentrating and spray drying at 60 ℃ and 8MPa to obtain mixed powder;
adding the rest components into the mixed powder, mixing, cooling at 15 deg.C under 45% humidity, and packaging to obtain the children formula milk powder.
Example 4
Children formula milk powder capable of promoting height development and enhancing immunity
The children formula milk powder for promoting height development and enhancing immunity comprises the following components in parts by weight:
90 parts of milk powder, 5 parts of anhydrous cream, 0.008 part of lactoferrin, 0.04 part of hydrolyzed yolk powder, 0.04 part of DHA, 1.6 parts of milk calcium, 0.08 part of fruit powder, 0.025 part of colostrum basic protein, 0.005 part of N-acetylneuraminic acid, 0.012 part of lutein and 0.008 part of taurine; wherein each part of fruit powder comprises equal amount of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder;
the children formula milk powder also comprises Bifidobacterium animalis BB-12, wherein the content of Bifidobacterium animalis BB-12 is 8 × 106CFU/g。
Second, preparation method
The preparation method of the children formula milk powder for promoting height development and enhancing immunity comprises the following steps:
determining the using amount of raw milk corresponding to the milk powder according to the proportional relation of the milk powder prepared from the raw milk, then adding anhydrous cream and DHA into the raw milk, and homogenizing, performing bus disinfection and sterilization, concentrating and spray drying at 40 ℃ and 20MPa to obtain mixed powder;
adding the rest components into the mixed powder, mixing, cooling at 26 deg.C under 45% humidity, and packaging to obtain the children formula milk powder.
Example 5
Children formula milk powder capable of promoting height development and enhancing immunity
The children formula milk powder for promoting height development and enhancing immunity comprises the following components in parts by weight:
100 parts of milk powder, 4 parts of anhydrous cream, 0.010 part of lactoferrin, 0.05 part of hydrolyzed yolk powder, 0.03 part of DHA, 1.5 parts of milk calcium, 0.1 part of fruit powder, 0.022 part of colostrum basic protein, 0.008 part of N-acetylneuraminic acid, 0.01 part of lutein and 0.01 part of taurine; wherein each part of fruit powder comprises equal amount of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder and cherry powder;
the children formula milk powder also comprises Bifidobacterium animalis BB-12, wherein the content of Bifidobacterium animalis BB-12 is 6 x 106CFU/g。
Second, preparation method
The preparation method of the children formula milk powder for promoting height development and enhancing immunity comprises the following steps:
determining the using amount of raw milk corresponding to the milk powder according to the proportional relation of the milk powder prepared from the raw milk, then adding anhydrous cream and DHA into the raw milk, and homogenizing, performing bus disinfection and sterilization, concentrating and spray drying at 50 ℃ and 10MPa to obtain mixed powder;
adding the rest components into the mixed powder, mixing, cooling at 20 deg.C and 50% humidity, and packaging to obtain the children formula milk powder.
The children formula milk powder prepared by the embodiment of the invention can supplement nutrition required by growth and development of children through selection of all raw materials, and the nutrient substances are rich and easy to absorb; in addition, the children formula milk powder also contains nutrient substances required by immune system establishment, and the combined action of all the components can effectively improve the autoimmunity of children and enhance the physique.
In addition, the children formula milk powder can effectively promote the thriving of children and the height development of children under the combined action of various aspects of nutrient substances, high calcium content, absorption promotion and physique enhancement.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (10)
1. The children formula milk powder capable of promoting height development and enhancing immunity is characterized by comprising the following components in parts by weight:
80-120 parts of milk powder, 2-6 parts of anhydrous cream, 0.005-0.015 part of lactoferrin, 0.03-0.06 part of hydrolyzed yolk powder, 0.01-0.05 part of DHA, 1-2 parts of milk calcium, 0.05-0.15 part of fruit powder, 0.015-0.03 part of primary emulsion basic protein, 0.003-0.010 part of N-acetylneuraminic acid, 0.005-0.015 part of lutein and 0.005-0.015 part of taurine.
2. The children's formula milk powder according to claim 1, comprising the following components in parts by weight:
90-110 parts of milk powder, 3-5 parts of anhydrous cream, 0.008-0.010 part of lactoferrin, 0.04-0.06 part of hydrolyzed yolk powder, 0.02-0.04 part of DHA, 1.2-1.6 parts of milk calcium, 0.08-0.12 part of fruit powder, 0.02-0.025 part of colostrum basic protein, 0.005-0.010 part of N-acetylneuraminic acid, 0.008-0.012 part of lutein and 0.008-0.012 part of taurine.
3. The children's formula milk powder according to claim 1, comprising the following components in parts by weight:
100 parts of milk powder, 4 parts of anhydrous cream, 0.010 part of lactoferrin, 0.05 part of hydrolyzed yolk powder, 0.03 part of DHA, 1.5 parts of milk calcium, 0.1 part of fruit powder, 0.022 part of colostrum basic protein, 0.008 part of N-acetylneuraminic acid, 0.01 part of lutein and 0.01 part of taurine.
4. The children's formula milk powder according to any one of claims 1 or 3, wherein the children's formula milk powder further comprises Bifidobacterium animalis BB-12, and the content of the Bifidobacterium animalis BB-12 is (1-10) x 106CFU/g。
5. The children's formula milk powder of claim 1, wherein the fruit powder comprises at least one of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder, and cherry powder.
6. The children's formula milk powder of claim 6, wherein the fruit powder comprises equal amounts of apple powder, mango powder, peach powder, sweet orange powder, banana powder, orange powder, papaya powder, pineapple powder, red grape powder, snow pear powder, lemon powder, strawberry powder, plum powder, blueberry powder, and cherry powder.
7. The method for preparing a children's formula milk powder according to any one of claims 1 to 6, comprising the steps of:
adding anhydrous cream and DHA into raw milk, homogenizing, sterilizing, concentrating, and spray drying to obtain mixed powder;
and adding the rest components into the mixed powder, uniformly mixing, cooling, and packaging to obtain the children formula milk powder.
8. The method according to claim 7, wherein the homogenization temperature is 40 to 60 ℃ and the pressure is 8 to 20 MPa.
9. The method according to claim 7, wherein the sterilization temperature is 90 to 93 ℃.
10. The preparation method of claim 7, wherein the ambient temperature of the bean jelly is 15-26 ℃ and the humidity is 45-60%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110931305.4A CN113662044A (en) | 2021-08-13 | 2021-08-13 | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110931305.4A CN113662044A (en) | 2021-08-13 | 2021-08-13 | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113662044A true CN113662044A (en) | 2021-11-19 |
Family
ID=78542723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110931305.4A Pending CN113662044A (en) | 2021-08-13 | 2021-08-13 | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662044A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624066A (en) * | 2022-10-31 | 2023-01-20 | 陈中明 | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112056403A (en) * | 2020-07-15 | 2020-12-11 | 湖南万婴宝品牌运营管理有限公司 | Novel formula of children's milk powder for promoting growth of high-blood fat |
| CN112471259A (en) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | Formula milk powder for promoting growth of height of children and preparation method thereof |
| CN112841324A (en) * | 2021-02-08 | 2021-05-28 | 西安佑益蓓食品有限公司 | Formula milk powder for children growth and preparation method thereof |
-
2021
- 2021-08-13 CN CN202110931305.4A patent/CN113662044A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112056403A (en) * | 2020-07-15 | 2020-12-11 | 湖南万婴宝品牌运营管理有限公司 | Novel formula of children's milk powder for promoting growth of high-blood fat |
| CN112471259A (en) * | 2020-11-25 | 2021-03-12 | 中宁县黄河乳制品有限公司 | Formula milk powder for promoting growth of height of children and preparation method thereof |
| CN112841324A (en) * | 2021-02-08 | 2021-05-28 | 西安佑益蓓食品有限公司 | Formula milk powder for children growth and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115624066A (en) * | 2022-10-31 | 2023-01-20 | 陈中明 | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
| AU771583B2 (en) | Bone resorption suppressing agent | |
| CA2306720A1 (en) | Supplement for restoring growth hormone levels | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN113632851A (en) | Multifunctional children growth milk powder and preparation method thereof | |
| CN110235943A (en) | A kind of anti-aging Yoghourt and preparation method thereof containing converted starch | |
| CN115624066A (en) | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof | |
| CN101077186A (en) | Egg white vinegar liquid | |
| CN113662044A (en) | Child formula milk powder for promoting height development and enhancing immunity and preparation method thereof | |
| CN105432792A (en) | Basic nutrition milk powder for preschool children, nutrition milk powder suit and preparation methods | |
| CN112385843A (en) | Balanced nutrition powder containing composite prebiotics and preparation method thereof | |
| US20070280997A1 (en) | Composition for enhancing muscle recovery | |
| CN116686876A (en) | Children formula milk powder capable of improving attention and preparation method thereof | |
| CN1943695A (en) | A tortoise preparation and its production technology | |
| CN107897588A (en) | Black ginseng garlic drinks and preparation method thereof | |
| KR100363998B1 (en) | Beverage composition for improving degenerative arthritis and method thereof | |
| CN107184656A (en) | It is a kind of to be used for hypotensive, blood fat, tea of blood glucose and preparation method thereof | |
| CN102763845A (en) | Seabuckthorn fruit oil and propolis soft capsule | |
| CN102948733B (en) | Production method and formula of special-eating life nutrition liquid | |
| CN111035017A (en) | Oral liquid for preventing and treating muscle loss | |
| CN111109490A (en) | Soybean lecithin solid beverage | |
| CN101167493A (en) | Dairy product containing rich coenzyme Q10 and preparation method thereof | |
| US20110229587A1 (en) | Calcium Supplements for the Treatment of Diabetes | |
| KR20010079227A (en) | manufacturing method of a health supplement food for a chitosan and vitamin | |
| CN1241486C (en) | Method for preparing health-care milk powder with food sleeping-care function contg. meilatoning |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211119 |